ToxGenSolutions BV (TGS)

ToxGenSolutions (TGS) applies toxicogenomic approaches on human health problems to provide the customer with epigenetic biomarker fingerprints for application in novel, more accurate, methods for the particular diagnosis of their need. TGS aims to develop novel and innovative epigenetic profiles hallmarking high-impact chronic and rare neurodevelopmental diseases to serve as early, preclinical, diagnostic verdicts of a disease. With the development of these novel tools, TGS aims to bridge the frequently large gap towards disease progression and therapeutic intervention. TGS provides novel epigenetic diagnostic methods for the early identification of pressing high-impact pathologies including cancer, neurodegeneration and immune-dysfunction, before irreversible disease-specific alterations in patient physiology have occurred. By doing this, we aim to provide an optimal perspective for patient healthcare as well as follow-up programs and preventative therapeutic interventions.